80.22 USD
-0.26 (-0.32%)
At close: Feb 10, 2026
80.22 USD
0 (0%)
After Hours: 2/10/2026, 8:12:12 PM
HALO gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While HALO has a great profitability rating, there are some minor concerns on its financial health. HALO is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, HALO could be worth investigating further for value and growth investing!.
1. Profitability
1.1 Basic Checks
- In the past year HALO was profitable.
- HALO had a positive operating cash flow in the past year.
- HALO had positive earnings in each of the past 5 years.
- In the past 5 years HALO always reported a positive cash flow from operatings.
1.2 Ratios
- With an excellent Return On Assets value of 26.81%, HALO belongs to the best of the industry, outperforming 97.71% of the companies in the same industry.
- With an excellent Return On Equity value of 118.17%, HALO belongs to the best of the industry, outperforming 99.62% of the companies in the same industry.
- Looking at the Return On Invested Capital, with a value of 42.77%, HALO belongs to the top of the industry, outperforming 99.24% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for HALO is in line with the industry average of 18.27%.
- The 3 year average ROIC (17.81%) for HALO is below the current ROIC(42.77%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROIC | 42.77% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
1.3 Margins
- HALO's Profit Margin of 47.91% is amongst the best of the industry. HALO outperforms 98.28% of its industry peers.
- HALO's Profit Margin has declined in the last couple of years.
- HALO has a better Operating Margin (59.33%) than 100.00% of its industry peers.
- HALO's Operating Margin has declined in the last couple of years.
- HALO's Gross Margin of 84.55% is amongst the best of the industry. HALO outperforms 87.19% of its industry peers.
- HALO's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% |
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
2. Health
2.1 Basic Checks
- HALO has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
- The number of shares outstanding for HALO has been reduced compared to 1 year ago.
- HALO has less shares outstanding than it did 5 years ago.
- HALO has a better debt/assets ratio than last year.
2.2 Solvency
- HALO has an Altman-Z score of 5.54. This indicates that HALO is financially healthy and has little risk of bankruptcy at the moment.
- HALO has a better Altman-Z score (5.54) than 74.19% of its industry peers.
- HALO has a debt to FCF ratio of 2.51. This is a good value and a sign of high solvency as HALO would need 2.51 years to pay back of all of its debts.
- HALO has a better Debt to FCF ratio (2.51) than 92.93% of its industry peers.
- A Debt/Equity ratio of 1.59 is on the high side and indicates that HALO has dependencies on debt financing.
- HALO has a worse Debt to Equity ratio (1.59) than 76.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Altman-Z | 5.54 |
ROIC/WACC3.65
WACC11.71%
2.3 Liquidity
- HALO has a Current Ratio of 1.59. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of HALO (1.59) is worse than 79.54% of its industry peers.
- HALO has a Quick Ratio of 1.37. This is a normal value and indicates that HALO is financially healthy and should not expect problems in meeting its short term obligations.
- HALO's Quick ratio of 1.37 is on the low side compared to the rest of the industry. HALO is outperformed by 80.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 48.55% over the past year.
- The Earnings Per Share has been growing by 30.12% on average over the past years. This is a very strong growth
- Looking at the last year, HALO shows a very strong growth in Revenue. The Revenue has grown by 31.19%.
- Measured over the past years, HALO shows a very strong growth in Revenue. The Revenue has been growing by 38.95% on average per year.
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
3.2 Future
- HALO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.78% yearly.
- Based on estimates for the next years, HALO will show a quite strong growth in Revenue. The Revenue will grow by 13.23% on average per year.
EPS Next Y58.04%
EPS Next 2Y40.36%
EPS Next 3Y32.57%
EPS Next 5Y17.78%
Revenue Next Year38.12%
Revenue Next 2Y32.39%
Revenue Next 3Y25.48%
Revenue Next 5Y13.23%
3.3 Evolution
- Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 14.25, the valuation of HALO can be described as correct.
- Based on the Price/Earnings ratio, HALO is valued cheaper than 96.56% of the companies in the same industry.
- The average S&P500 Price/Earnings ratio is at 28.03. HALO is valued slightly cheaper when compared to this.
- Based on the Price/Forward Earnings ratio of 9.63, the valuation of HALO can be described as reasonable.
- HALO's Price/Forward Earnings ratio is rather cheap when compared to the industry. HALO is cheaper than 98.09% of the companies in the same industry.
- When comparing the Price/Forward Earnings ratio of HALO to the average of the S&P500 Index (27.97), we can say HALO is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.25 | ||
| Fwd PE | 9.63 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, HALO is valued cheaply inside the industry as 96.56% of the companies are valued more expensively.
- 96.94% of the companies in the same industry are more expensive than HALO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.66 | ||
| EV/EBITDA | 12.2 |
4.3 Compensation for Growth
- HALO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- The excellent profitability rating of HALO may justify a higher PE ratio.
- HALO's earnings are expected to grow with 32.57% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.25
PEG (5Y)N/A
EPS Next 2Y40.36%
EPS Next 3Y32.57%
5. Dividend
5.1 Amount
- No dividends for HALO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
80.22
-0.26 (-0.32%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)02-24 2026-02-24/amc
Inst Owners105.85%
Inst Owner Change-1.53%
Ins Owners0.81%
Ins Owner Change-0.62%
Market Cap9.43B
Revenue(TTM)1.24B
Net Income(TTM)595.49M
Analysts76
Price Target79.56 (-0.82%)
Short Float %11.69%
Short Ratio6.66
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.41%
Min EPS beat(2)3.56%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)11.06%
Min EPS beat(4)3.56%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)12.2%
EPS beat(12)10
Avg EPS beat(12)9.54%
EPS beat(16)13
Avg EPS beat(16)9.68%
Revenue beat(2)2
Avg Revenue beat(2)6.93%
Min Revenue beat(2)2.18%
Max Revenue beat(2)11.69%
Revenue beat(4)4
Avg Revenue beat(4)7.01%
Min Revenue beat(4)1.36%
Max Revenue beat(4)12.81%
Revenue beat(8)6
Avg Revenue beat(8)5.71%
Revenue beat(12)7
Avg Revenue beat(12)2.94%
Revenue beat(16)9
Avg Revenue beat(16)2.47%
PT rev (1m)2.63%
PT rev (3m)3.08%
EPS NQ rev (1m)14.96%
EPS NQ rev (3m)13.89%
EPS NY rev (1m)4.46%
EPS NY rev (3m)6.45%
Revenue NQ rev (1m)10.99%
Revenue NQ rev (3m)11.2%
Revenue NY rev (1m)3.21%
Revenue NY rev (3m)5.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.25 | ||
| Fwd PE | 9.63 | ||
| P/S | 7.59 | ||
| P/FCF | 15.66 | ||
| P/OCF | 15.44 | ||
| P/B | 18.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.2 |
EPS(TTM)5.63
EY7.02%
EPS(NY)8.33
Fwd EY10.39%
FCF(TTM)5.12
FCFY6.39%
OCF(TTM)5.2
OCFY6.48%
SpS10.57
BVpS4.28
TBVpS-2.22
PEG (NY)0.25
PEG (5Y)N/A
Graham Number23.3
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.81% | ||
| ROE | 118.17% | ||
| ROCE | 53.28% | ||
| ROIC | 42.77% | ||
| ROICexc | 86.79% | ||
| ROICexgc | N/A | ||
| OM | 59.33% | ||
| PM (TTM) | 47.91% | ||
| GM | 84.55% | ||
| FCFM | 48.47% |
ROA(3y)16.25%
ROA(5y)21.49%
ROE(3y)192.36%
ROE(5y)173.4%
ROIC(3y)17.81%
ROIC(5y)29.79%
ROICexc(3y)23.94%
ROICexc(5y)N/A
ROICexgc(3y)71.73%
ROICexgc(5y)N/A
ROCE(3y)22.19%
ROCE(5y)37.11%
ROICexgc growth 3Y-1.13%
ROICexgc growth 5YN/A
ROICexc growth 3Y-28.16%
ROICexc growth 5YN/A
OM growth 3Y-4.44%
OM growth 5YN/A
PM growth 3Y-21.62%
PM growth 5YN/A
GM growth 3Y1.07%
GM growth 5Y1.9%
F-Score8
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.59 | ||
| Debt/FCF | 2.51 | ||
| Debt/EBITDA | 0.98 | ||
| Cap/Depr | 10.51% | ||
| Cap/Sales | 0.69% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.59% | ||
| Profit Quality | 101.16% | ||
| Current Ratio | 1.59 | ||
| Quick Ratio | 1.37 | ||
| Altman-Z | 5.54 |
F-Score8
WACC11.71%
ROIC/WACC3.65
Cap/Depr(3y)13.62%
Cap/Depr(5y)33.32%
Cap/Sales(3y)1.21%
Cap/Sales(5y)0.98%
Profit Quality(3y)118.15%
Profit Quality(5y)93.9%
High Growth Momentum
Growth
EPS 1Y (TTM)48.55%
EPS 3Y30.12%
EPS 5YN/A
EPS Q2Q%35.43%
EPS Next Y58.04%
EPS Next 2Y40.36%
EPS Next 3Y32.57%
EPS Next 5Y17.78%
Revenue 1Y (TTM)31.19%
Revenue growth 3Y31.82%
Revenue growth 5Y38.95%
Sales Q2Q%22.12%
Revenue Next Year38.12%
Revenue Next 2Y32.39%
Revenue Next 3Y25.48%
Revenue Next 5Y13.23%
EBIT growth 1Y54.59%
EBIT growth 3Y25.97%
EBIT growth 5YN/A
EBIT Next Year61.82%
EBIT Next 3Y38.38%
EBIT Next 5Y15.57%
FCF growth 1Y70.36%
FCF growth 3Y16.28%
FCF growth 5YN/A
OCF growth 1Y65.76%
OCF growth 3Y16.96%
OCF growth 5YN/A
HALOZYME THERAPEUTICS INC / HALO FAQ
Can you provide the ChartMill fundamental rating for HALOZYME THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 7 / 10 to HALO.
Can you provide the valuation status for HALOZYME THERAPEUTICS INC?
ChartMill assigns a valuation rating of 9 / 10 to HALOZYME THERAPEUTICS INC (HALO). This can be considered as Undervalued.
Can you provide the profitability details for HALOZYME THERAPEUTICS INC?
HALOZYME THERAPEUTICS INC (HALO) has a profitability rating of 8 / 10.
What is the financial health of HALOZYME THERAPEUTICS INC (HALO) stock?
The financial health rating of HALOZYME THERAPEUTICS INC (HALO) is 6 / 10.
Can you provide the expected EPS growth for HALO stock?
The Earnings per Share (EPS) of HALOZYME THERAPEUTICS INC (HALO) is expected to grow by 58.04% in the next year.